Drugs / GamEvac-Combi
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT03072030 | Aug 2017 → Dec 2019 | Ebola hemorrhagic fever | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GamEvac-Combi | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03072030 ↗ |
| Modality | Vaccine | “METHODS: A double-blind randomized placebo-controlled trial was performed to evaluate safety and immunogenicity of rVSV- and rAd5-vectored vaccine GamEvac-Combi in healthy...” PMID 40207235 ↗ Mar 2025 |